Table 2.

Coagulation study results in patients with prolonged (≥ Grade 2) aPTT

Coagulation test	Number of patients with an abnormal result per local or central testing	Normal ranges	Median (min, max)a
aPL (n = 23)
dRVVT (confirmatory result; n = 8b)	8	ratio < 1.21	1.63 (1.24, 2.01) n = 6
Hexagonal phase phospholipids (n = 15)	15	0–11 s	48 (18, 129) n = 15
aCL IgG (n = 17)	0	< 15 GPL (indeterminate 15–20 GPL)	10 (10, 10) n = 14
aCL IgM (n = 17)	2	< 13 MPL (indeterminate 13–20 MPL)	10 (10, 36) n = 14
aβ2GPI IgG (n = 17)	0	< 21 SGU	10 (10, 12) n = 14
aβ2GPI IgM (n = 17)	2	< 33 SMU	10 (10, 94) n = 14

aPL testing was not conducted for patients without prolonged aPTT. Testing for aCL and aβ2GPI was only conducted in patients with a positive aPL result. For aCL and aβ2GPI most values were reported as ‘<[ numeric value]’. Where available, central laboratory results were used in this table. For the median, numeric values after the symbol have been used. In the cases of a range, the higher value has been selected for the median calculation

aβ2GPI = anti-β2-glycoprotein I antibodies; aCL = anticardiolipin; aPL = antiphospholipid antibody; aPTT = activated partial thromboplastin time; dRVVT = Dilute Russell Viper Venom Time; GPL/MPL = IgG/IgM phospholipid unit; SGU/SMU = standard IgG/IgM aβ2GPI unit

^aResults only included in median (min, max) calculations if normal ranges match that of the central laboratory.

^bTwo patient had both dRVVT and hexagonal phase phospholipid tests conducted; the dRVVT results were used in this analysis.